A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS Mutant Melanoma

Cancer Research - United States
doi 10.1158/0008-5472.can-18-2711
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

816 Autophagy Inhibition Sensitizes Targeted Therapy-Resistant Melanoma to MEK1/2 Inhibitors

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

A Systematic Review on the Epidemiology of NRAS-Mutant Melanoma in Europe and Australia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

mTORC1/autophagy-regulated MerTK in Mutant BRAFV600 Melanoma With Acquired Resistance to BRAF Inhibition

Oncotarget
Oncology
2017English

MEK1 Mutations Confer Resistance to MEK and B-Raf Inhibition

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Loss of FAT1 Drives Resistance to CDK4/6 Inhibitors in Breast Cancer

Cancer Discovery
Oncology
2018English

645 MIG6 Is MEK-regulated and Affects EGF-induced Migration in Mutant NRAS Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2016English

MEK Inhibition Appears to Improve Symptom Control in Primary NRAS-driven CNS Melanoma in Children

British Journal of Cancer
Cancer ResearchOncology
2017English

CDK4/6 Inhibition in Cancer: The Cell Cycle Splicing Connection

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2019English

Acquired Resistance to BRAF Inhibition in BRAFV600E Mutant Gliomas

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy